FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317523048> ?p ?o ?g. }

• W4317523048 endingPage "1941" @default.
• W4317523048 startingPage "1934" @default.
• W4317523048 abstract "No AccessJournal of UrologyClinical Urology: Original Article1 Dec 1996A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder Cancer A. Pawinski, R. Sylvester, K.H. Kurth, C. Bouffioux, A. Van Der Meijden, M.K.B. Parmar, L. Bijnens, For the Members of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group†, and The Medical Research Council Working Party on Superficial Bladder Cancer‡ A. PawinskiA. Pawinski More articles by this author , R. SylvesterR. Sylvester More articles by this author , K.H. KurthK.H. Kurth More articles by this author , C. BouffiouxC. Bouffioux More articles by this author , A. Van Der MeijdenA. Van Der Meijden More articles by this author , M.K.B. ParmarM.K.B. Parmar More articles by this author , L. BijnensL. Bijnens More articles by this author , For the Members of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group† Study group coordinators: F. Debruyne, L. Denis, W. Oosterlinck and M. Robinson; superficial bladder subcommittee: M. Brausi, W. Holtl and R. van Velthoven, and group chairman: R. Hall. More articles by this author , and The Medical Research Council Working Party on Superficial Bladder Cancer‡ Coordinators: P. Smith, B. Richards and D. Tolley. More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65396-5AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The use of prophylactic agents after primary resection can decrease the incidence of tumor recurrence in patients with stage TaT1 bladder cancer. However, the long-term impact on progression to muscle invasive disease as well as on duration of survival is unknown. A combined analysis of individual patient data from previously performed European Organization for Research and Treatment of Cancer (EORTC) and Medical Research Council (MRC) randomized clinical trials was done in an attempt to answer these crucial questions. We compared immediate versus no adjuvant prophylactic treatment after transurethral resection with respect to disease-free interval, time to progression to muscle invasive disease, time to appearance of distant metastases, duration of survival and progression-free survival. Materials and Methods: All EORTC and MRC prophylactic, randomized phase III trials with primary or recurrent, stage TaT1 transitional cell bladder cancer that compared transurethral resection alone or with adjuvant prophylactic treatment were included in the study. Four EORTC and 2 MRC trials using intravesical chemotherapy or oral agents and including a total of 2,535 patients were studied. Results: A statistically significant effect of adjuvant treatment over no adjuvant treatment was found in terms of the duration of the disease-free interval (p less than 0.01). No clear advantage of adjuvant treatment was shown with respect to progression to invasive disease, time to appearance of distant metastases or duration of survival and progression-free survival. Median survival followup was 7.8 years. Conclusions: Despite prologation of the disease-free interval adjuvant treatment has no apparent long-term impact on the evolution of stage TaTi bladder cancer. References 1 : Cancer in the European community and its member states.. Eur. J. Cancer1990; 26: 1167. Google Scholar 2 : Cancer Facts & Figures--1995. Atlanta, Georgia: American Cancer Society1995. Google Scholar 3 : Does intravesical chemotherapy prevent invasive bladder cancer? J.. Urol.1984; 131: 33. Abstract, Google Scholar 4 Kurth, K. H., Denis, L., Ten Kate, F. F. J. W., Sylvester, R., De Pauw, M., Bouffioux, C., Debruyne, F. M. J., Pavone-Macaluso, M. and Oosterlinck, W.: Prognostic factors in superficial bladder tumors. In: Transitional Cell Malignancy. Edited by M. S. Soloway. Philadelphia, pp. 471-483, 1992. Google Scholar 5 : An overview of intravesical therapy for superficial bladder tumors.. J. Urol.1987; 138: 1363. Abstract, Google Scholar 6 : Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.. Eur. Urol.1982; 8: 207. Google Scholar 7 : A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta,T1 papillary carcinoma of the bladder. J. Urol.1993; 149: 749. Abstract, Google Scholar 8 : Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of an European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J. Urol.1984; 132: 258. Abstract, Google Scholar 9 : Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective randomised phase III study performed by the EORTC GU Group. EORTC Genitourinary Tract Cancer Cooperative Group. Eur. Urol.1995; 27: 110. Google Scholar 10 : The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC study. Brit. J. Urol.1985; 57: 680. Google Scholar 11 : The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomised trial. Brit. J. Urol.1994; 73: 632. Google Scholar 12 : Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).. Brit. Med. J.1988; 296: 1759. Google Scholar 13 : Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of European Organization for Research and Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. J. Urol.1992; 148: 297. Abstract, Google Scholar 14 : Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J. Urol.1995; 153: 934. part 2. Link, Google Scholar 15 : BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. Urology1988; : 20. Google Scholar 16 : Meta-analysis: the fashion of summing-up evidence. Part I: rationale and conduct. Ann. Oncol.1991; 2: 461. Google Scholar 17 : TNM Classification of Malignant Tumours. Geneva: Imprimerie G. de Buren1978. Google Scholar 18 : Beta blockade during and after myocardial infarction: an overview of the randomized trials.. Prog. Cardiovasc. Dis.1985; 27: 335. Google Scholar 19 : Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.. New Engl. J. Med.1988; 319: 1681. Google Scholar 20 : Non-parametric estimation from incomplete observations.. J. Amer. Stat. Ass.1958; 53: 457. Google Scholar 21 : . Oxford: Oxford University Press1990. Google Scholar 22 : Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.. Cancer1990; 65: 23. Google Scholar 23 : The effect of intravesical instillations of thiotepa, mitomycin C, and Adriamycin on normal urothelium: an experimental study in rats.. J. Urol.1991; 145: 1060. Abstract, Google Scholar 24 : The effect of mitomycin C on superficial bladder cancer.. J. Urol.1981; 125: 646. Abstract, Google Scholar 25 : A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder.. New Engl. J. Med.1991; 325: 1205. Google Scholar 26 : Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a perspective randomized trial.. J. Clin. Oncol.1995; 13: 1404. Google Scholar 27 : Intravesical therapy: does it affect the natural history of superficial bladder cancer? Sem.. Urol.1992; 10: 39. Google Scholar 28 : A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J.. Urol.1991; 146: 32. Abstract, Google Scholar 29 : Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.. J. Urol.1990; 143: 502. Google Scholar 30 : MMC and BCG in Intravesical Chemotherapy and Immunotherapy of Superficial Bladder Cancer.. In: EORTC GU Group Monograph 6.. New York: Alan R. Liss, Inc.1989: 271. Google Scholar 31 : Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.. J. Urol.1987; 137: 871. Abstract, Google Scholar 32 : Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder.. Urol. Oncol.1995; 1: 119. Google Scholar Department of Urology, Memorial Cancer Center, Warsaw, Poland; European Organization for Research and Treatment of Cancer Data Center, Brussels and Hopital Universitaire, Liege, Belgium; Academisch Medisch Centrum, Amsterdam and Groot Ziekengasthuis, Hertogenbosch, The Netherlands, and Medical Research Councel Cancer Trials Office, Cambridge, United Kingdom.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byLamm D, Persad R, Brausi M, Buckley R, Witjes J, Palou J, Böhle A, Kamat A, Colombel M and Soloway M (2018) Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard DefinitionJournal of Urology, VOL. 191, NO. 1, (20-27), Online publication date: 1-Jan-2014.Brausi M, Witjes J, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A (2018) A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer GroupJournal of Urology, VOL. 186, NO. 6, (2158-2167), Online publication date: 1-Dec-2011.Koya M, Simon M and Soloway M (2018) Complications of Intravesical Therapy for Urothelial Cancer of the BladderJournal of Urology, VOL. 175, NO. 6, (2004-2010), Online publication date: 1-Jun-2006.PALOU J, CARCAS A, SEGARRA J, DUQUE B, SALVADOR J, GARCIA-RIBAS I and VILLAVICENCIO H (2018) PHASE I PHARMACOKINETIC STUDY OF A SINGLE INTRAVESICAL INSTILLATION OF GEMCITABINE ADMINISTERED IMMEDIATELY AFTER TRANSURETHRAL RESECTION PLUS MULTIPLE RANDOM BIOPSIES IN PATIENTS WITH SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 172, NO. 2, (485-488), Online publication date: 1-Aug-2004.BÖHLE A, JOCHAM D and BOCK P (2018) Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and ToxicityJournal of Urology, VOL. 169, NO. 1, (90-95), Online publication date: 1-Jan-2003.GRIMM M, STEINHOFF C, SIMON X, SPIEGELHALDER P, ACKERMANN R and VÖGELI T (2018) Effect of Routine Repeat Transurethral Resection for Superficial Bladder Cancer: A Long-term Observational StudyJournal of Urology, VOL. 170, NO. 2, (433-437), Online publication date: 1-Aug-2003.DAVIS J, SHETH S, DOVIAK M and SCHELLHAMMER P (2018) SUPERFICIAL BLADDER CARCINOMA TREATED WITH BACILLUS CALMETTE-GUERIN: PROGRESSION-FREE AND DISEASE SPECIFIC SURVIVAL WITH MINIMUM 10-YEAR FOLLOWUPJournal of Urology, VOL. 167, NO. 2 Part 1, (494-501), Online publication date: 1-Feb-2002.SYLVESTER R, van der MEIJDEN A and LAMM D (2018) Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, VOL. 168, NO. 5, (1964-1970), Online publication date: 1-Nov-2002.Goebell P, Otto T, Suhr J and Rübben H (2018) Evaluation of an Unconventional Treatment Modality with Mistletoe Lectin to Prevent Recurrence of Superficial Bladder Cancer: A Randomized Phase ii TrialJournal of Urology, VOL. 168, NO. 1, (72-75), Online publication date: 1-Jul-2002.VAN DER MEIJDEN A, BRAUSI M, ZAMBON V, KIRKELS W, DE BALINCOURT C and SYLVESTER R (2018) INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIALJournal of Urology, VOL. 166, NO. 2, (476-481), Online publication date: 1-Aug-2001.DUGGAN B, KELLY J, KEANE P and JOHNSTON S (2018) MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCERJournal of Urology, VOL. 165, NO. 3, (946-954), Online publication date: 1-Mar-2001.VAN DER MEIJDEN A, SYLVESTER R, COLLETTE L, BONO A and TEN KATE F (2018) THE ROLE AND IMPACT OF PATHOLOGY REVIEW ON STAGE AND GRADE ASSESSMENT OF STAGES TA AND T1 BLADDER TUMORS: A COMBINED ANALYSIS OF 5 EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER TRIALSJournal of Urology, VOL. 164, NO. 5, (1533-1537), Online publication date: 1-Nov-2000.MILLÁN-RODRÍGUEZ F, CHÉCHILE-TONIOLO G, SALVADOR-BAYARRI J, PALOU J, ALGABA F and VICENTE-RODRÍGUEZ J (2018) PRIMARY SUPERFICIAL BLADDER CANCER RISK GROUPS ACCORDING TO PROGRESSION, MORTALITY AND RECURRENCEJournal of Urology, VOL. 164, NO. 3 Part 1, (680-684), Online publication date: 1-Sep-2000.LAMM D, BLUMENSTEIN B, CRISSMAN J, MONTIE J, GOTTESMAN J, LOWE B, SAROSDY M, BOHL R, GROSSMAN H, BECK T, LEIMERT J and CRAWFORD E (2018) MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, VOL. 163, NO. 4, (1124-1129), Online publication date: 1-Apr-2000.MILLÁN-RODRÍGUEZ F, CHÉCHILE-TONIOLO G, SALVADOR-BAYARRI J, PALOU J and VICENTE-RODRÍGUEZ J (2018) MULTIVARIATE ANALYSIS OF THE PROGNOSTIC FACTORS OF PRIMARY SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 163, NO. 1, (73-78), Online publication date: 1-Jan-2000.MALMSTROM P, WIJKSTROM H, LUNDHOLM C, WESTER K, BUSCH C and NORLEN B (2018) 5-YEAR FOLLOWUP OF A RANDOMIZED PROSPECTIVE STUDY COMPARING MITOMYCIN C AND BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER CARCINOMAJournal of Urology, VOL. 161, NO. 4, (1124-1127), Online publication date: 1-Apr-1999.WITJES J, CARIS C, MUNGAN N, DEBRUYNE F and WITJES W (2018) RESULTS OF A RANDOMIZED PHASE III TRIAL OF SEQUENTIAL INTRAVESICAL THERAPY WITH MITOMYCIN C AND BACILLUS CALMETTE-GUERIN VERSUS MITOMYCIN C ALONE IN PATIENTS WITH SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 160, NO. 5, (1668-1672), Online publication date: 1-Nov-1998. (2018) EDITORIAL COMMENTJournal of Urology, VOL. 158, NO. 1, (73-74), Online publication date: 1-Jul-1997. Volume 156Issue 6December 1996Page: 1934-1941 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information A. Pawinski More articles by this author R. Sylvester More articles by this author K.H. Kurth More articles by this author C. Bouffioux More articles by this author A. Van Der Meijden More articles by this author M.K.B. Parmar More articles by this author L. Bijnens More articles by this author For the Members of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group† Study group coordinators: F. Debruyne, L. Denis, W. Oosterlinck and M. Robinson; superficial bladder subcommittee: M. Brausi, W. Holtl and R. van Velthoven, and group chairman: R. Hall. More articles by this author The Medical Research Council Working Party on Superficial Bladder Cancer‡ Coordinators: P. Smith, B. Richards and D. Tolley. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4317523048 created "2023-01-20" @default.
• W4317523048 creator A5004584899 @default.
• W4317523048 creator A5014097745 @default.
• W4317523048 creator A5018057184 @default.
• W4317523048 creator A5046065242 @default.
• W4317523048 creator A5046387200 @default.
• W4317523048 creator A5077321647 @default.
• W4317523048 creator A5091674188 @default.
• W4317523048 date "1996-12-01" @default.
• W4317523048 modified "2023-10-14" @default.
• W4317523048 title "A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder Cancer" @default.
• W4317523048 cites W1781424562 @default.
• W4317523048 cites W182727707 @default.
• W4317523048 cites W1966953116 @default.
• W4317523048 cites W1973003019 @default.
• W4317523048 cites W1980368600 @default.
• W4317523048 cites W2012262060 @default.
• W4317523048 cites W2016995945 @default.
• W4317523048 cites W2051352978 @default.
• W4317523048 cites W214881549 @default.
• W4317523048 cites W2305444527 @default.
• W4317523048 cites W2333193688 @default.
• W4317523048 cites W2398691199 @default.
• W4317523048 cites W2406405012 @default.
• W4317523048 cites W2414093763 @default.
• W4317523048 cites W2417407414 @default.
• W4317523048 cites W2425308505 @default.
• W4317523048 cites W2427654450 @default.
• W4317523048 cites W2437194999 @default.
• W4317523048 cites W2442720469 @default.
• W4317523048 cites W2471659321 @default.
• W4317523048 cites W2901368272 @default.
• W4317523048 cites W3041047318 @default.
• W4317523048 cites W4243691565 @default.
• W4317523048 cites W4244617181 @default.
• W4317523048 cites W96272399 @default.
• W4317523048 doi "https://doi.org/10.1016/s0022-5347(01)65396-5" @default.
• W4317523048 hasPublicationYear "1996" @default.
• W4317523048 type Work @default.
• W4317523048 citedByCount "174" @default.
• W4317523048 countsByYear W43175230482012 @default.
• W4317523048 countsByYear W43175230482013 @default.
• W4317523048 countsByYear W43175230482014 @default.
• W4317523048 countsByYear W43175230482015 @default.
• W4317523048 countsByYear W43175230482016 @default.
• W4317523048 countsByYear W43175230482017 @default.
• W4317523048 countsByYear W43175230482018 @default.
• W4317523048 countsByYear W43175230482019 @default.
• W4317523048 countsByYear W43175230482021 @default.
• W4317523048 countsByYear W43175230482022 @default.
• W4317523048 countsByYear W43175230482023 @default.
• W4317523048 crossrefType "journal-article" @default.
• W4317523048 hasAuthorship W4317523048A5004584899 @default.
• W4317523048 hasAuthorship W4317523048A5014097745 @default.
• W4317523048 hasAuthorship W4317523048A5018057184 @default.
• W4317523048 hasAuthorship W4317523048A5046065242 @default.
• W4317523048 hasAuthorship W4317523048A5046387200 @default.
• W4317523048 hasAuthorship W4317523048A5077321647 @default.
• W4317523048 hasAuthorship W4317523048A5091674188 @default.
• W4317523048 hasConcept C121608353 @default.
• W4317523048 hasConcept C126322002 @default.
• W4317523048 hasConcept C143998085 @default.
• W4317523048 hasConcept C146357865 @default.
• W4317523048 hasConcept C151730666 @default.
• W4317523048 hasConcept C168563851 @default.
• W4317523048 hasConcept C177713679 @default.
• W4317523048 hasConcept C2780352672 @default.
• W4317523048 hasConcept C29456083 @default.
• W4317523048 hasConcept C2982822547 @default.
• W4317523048 hasConcept C502991105 @default.
• W4317523048 hasConcept C535046627 @default.
• W4317523048 hasConcept C71924100 @default.
• W4317523048 hasConcept C86803240 @default.
• W4317523048 hasConceptScore W4317523048C121608353 @default.
• W4317523048 hasConceptScore W4317523048C126322002 @default.
• W4317523048 hasConceptScore W4317523048C143998085 @default.
• W4317523048 hasConceptScore W4317523048C146357865 @default.
• W4317523048 hasConceptScore W4317523048C151730666 @default.
• W4317523048 hasConceptScore W4317523048C168563851 @default.
• W4317523048 hasConceptScore W4317523048C177713679 @default.
• W4317523048 hasConceptScore W4317523048C2780352672 @default.
• W4317523048 hasConceptScore W4317523048C29456083 @default.
• W4317523048 hasConceptScore W4317523048C2982822547 @default.
• W4317523048 hasConceptScore W4317523048C502991105 @default.
• W4317523048 hasConceptScore W4317523048C535046627 @default.
• W4317523048 hasConceptScore W4317523048C71924100 @default.
• W4317523048 hasConceptScore W4317523048C86803240 @default.
• W4317523048 hasIssue "6" @default.
• W4317523048 hasLocation W43175230481 @default.
• W4317523048 hasOpenAccess W4317523048 @default.
• W4317523048 hasPrimaryLocation W43175230481 @default.
• W4317523048 hasRelatedWork W1979321249 @default.
• W4317523048 hasRelatedWork W2135322747 @default.
• W4317523048 hasRelatedWork W2356105190 @default.
• W4317523048 hasRelatedWork W2474195589 @default.
• W4317523048 hasRelatedWork W2800502062 @default.
• W4317523048 hasRelatedWork W3159250744 @default.

• next